

Chugai Pharmabody Research At the forefront of global research Established in 2012, CPR is a subsidiary of Chugai Pharmaceutical

Driven by a desire to improve patients' lives



CPR discovers drugs to tackle unmet medical needs:



Cancer



Inflammatory diseases




Fibrotic diseases



Genetic diseases





Always a step ahead of others by redefining the approach to drug discovery

Unlike conventional antibody technology which limits druggable targets, our proprietary technologies enable us to expand the drug target universe

Our proprietary technologies expand the drug universe

Antibody Engineering Technology



Recycling Antibody **Technology**

only bind once

allows a single antibody molecule to bind multiple times to an antigen unlike conventional antibodies which can


Bispecific Antibody **Technology**

enables unique modes

of action by binding to two different antigens at the same time

Switch Antibody **Technology**

not elsewhere






allows a recycling antibody to efficiently sweep away and eliminate antigens from the plasma which cannot be achieved by conventional antibodies


T-cell Redirecting **Antibody Technology**

potently kills cancer cells by binding to various tumor antigens and redirecting T cells to eliminate them



Cyclic Peptide Technology

We are pioneers in mid-size molecule drug discovery -



Location

3 Biopolis Drive #07-11 to 16, Synapse

Singapore 138623

Contact details

: +65 6933 4888 contact@chugai-pharmabody.com **Discover** our work in detail:

